注：EASI75/90/100，湿疹面积和严重程度指数较基线改善≥75%/≥90%/100%；UPA，乌帕替尼；PBO，安慰剂
图1 乌帕替尼治疗青少年中重度AD患者第76周EASI75、EASI90、EASI100应答率（数据来源：参考文献7）
注：vIGA-AD 0/1，经验证的特应性皮炎研究者整体评估为清除（0）或几乎清除（1）且较基线改善≥2；WP-NRS，最严重瘙痒数值评定量表；UPA，乌帕替尼；PBO，安慰剂
图2 乌帕替尼治疗青少年中重度AD患者第76周vIGA-AD 0/1和WP-NRS改善≥4应答率（数据来源：参考文献7）
注：AE，不良事件；SAE，严重不良事件；UPA，乌帕替尼；TCS，外用糖皮质激素；E/100PY，每100患者年发生事件
图3 乌帕替尼治疗青少年中重度AD患者76周的总体安全性（数据来源：参考文献7）
参考文献：
[1] Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study[J]. Ann Allergy Asthma Immunol, 2021,126(4):417-428.e2. doi: 10.1016/j.anai.2020.12.020.
[2] 中华医学会皮肤性病学分会儿童皮肤病学组. 中国儿童特应性皮炎诊疗共识(2017版)[J]. 中华皮肤科杂志, 2017,50(11):784-789. doi: 10.3760/cma.j.issn.0412-4030.2017.11.002.
[3] Weidinger S, Simpson EL, Silverberg JI, et al. Burden of atopic dermatitis in paediatric patients: an international cross-sectional study[J]. Br J Dermatol, 2024,190(6):846-857. doi: 10.1093/bjd/ljad449.
[4] 中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组, 中国老年保健医学研究会皮肤科分会. 系统Janus激酶抑制剂治疗特应性皮炎专家共识[J]. 实用皮肤病学杂志, 2022,15(3):129-135. doi: 10.11786/sypfbxzz.1674-1293.20220301.
[5] 中国医师协会皮肤科医师分会, 中华医学会皮肤性病学分会, 中国医疗保健国际交流促进会皮肤医学分会, 等. 特应性皮炎治疗药物应用管理专家共识（2024版）[J]. 中华皮肤科杂志, 2024,57(2):97-108. doi: 10.35541/cjd.20230358.
[6] Paller AS, Ladizinski B, Mendes-Bastos P, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the Measure Up 1, Measure Up 2, and AD Up randomized clinical trials[J]. JAMA Dermatol, 2023,159(5):526-535. doi: 10.1001/jamadermatol.2023.0391.
[7] Paller AS, Mendes-Bastos P, Siegfried E, et al. Upadacitinib in adolescents with moderate to severe atopic dermatitis: analysis of 3 phase 3 randomized clinical trials through 76 weeks[J]. JAMA Dermatol, 2024,160(12):1304-1313. doi: 10.1001/jamadermatol.2024.3696.
[8] Silverberg JI, Guttman-Yassky E, Simpson EL, et al. Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results[J]. Br J Dermatol, 190(Suppl_2): ii8. doi: 10.1093/bjd/ljad498.010.
[9] Hong HC, Magnolo N, Silvestre JF, et al. Efficacy and safety of upadacitinib in adolescents with moderate-to-severe atopic dermatitis versus dupilumab[EB/OL]. [2024-10-25]. https://abbvie1.outsystemsenterprise.com/CongressPublications/MaterialActions?ConferenceId=4041&MaterialsId=7100.
[10] Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the Measure Up 1 and Measure Up 2 randomized clinical trials[J]. JAMA Dermatol, 2022,158(4):404-413. doi: 10.1001/jamadermatol.2022.0029.
[11] Silverberg JI, de Bruin-Weller M, Bieber T, et al. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results[J]. J Allergy Clin Immunol, 2022,149(3):977-987.e14. doi: 10.1016/j.jaci.2021.07.036.
本材料仅供中国大陆境内的医疗卫生专业人员作为学术参考，而非针对一般公众，亦非广告用途。医疗卫生专业人员在做出任何与治疗有关的决定时，应根据患者的具体情况，参照药监局核准的药品说明书。如果您不是卫生医疗专业人士，请勿阅读和/或传播本材料。
